
Anticoagulation Therapy Outcomes
Provided By: John Snow Labs

Anticoagulation Therapy Outcomes
Provided By: John Snow Labs
This data package is about anticoagulant therapy. It includes following datasets: patients with and without hematoma enlargement, chronic care management differences and patient outcomes in anticoagulant clinics, participant characteristics anticoagulants randomized trial, pulmonary embolism thrombolysis treatment and its complications.
Product offers
The following offers are available for this product. Choose an offer to view the pricing and access duration options for the offer. Select an offer and continue to subscribe. Your subscription begins on the date that you accept the offer. Additional taxes or fees might apply.
Public offer
Payment schedule: Upfront payment | Offer auto-renewal: Supported
$0 for 12 months
Overview
Overview
This data package is a collection of numerous studies related to anticoagulation therapy. The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed a study on behalf of IGNITE (Initiative of German Neuro-intensive Trial Engagement). The study investigated the association of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and the effects of OAC resumption. Another study compared outcome for patients using two different mode of reversal treatments: (1) Fresh Frozen Plasma (FFP), and (2) Prothrombin Complex Concentrates (PCC). A research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy. The data were subjected to regression analysis to identify to what extent the differences in patient outcomes are associated with chronic care management activities. Another study was performed to identify the differences in patient outcomes and their relationship with chronic care management of oral anticoagulant. The goal of another study was to perform a systematic review of the literature and determine pre-specified inclusion criteria based on relevant studies, which are as follows: randomized controlled design in patients with PE evaluating thrombolytic therapy as an intervention; a comparator group that included any of the following agents: low-molecular-weight heparin (LMWH), vitamin K antagonist, fondaparinux, or unfractionated heparin; and reporting of mortality outcomes. We did not include trials that compared different thrombolytic agents against one another or different doses of the same thrombolytic drug.
License Information
The use of John Snow Labs datasets is free for personal and research purposes. For commercial use please subscribe to the Data Library on AWS. The subscription will allow you to use all John Snow Labs datasets and data packages for commercial purposes.
Metadata
Description | Value |
---|---|
Data Package Complexity | Simple |
Available Enrichments | N/A |
Keywords | Anticoagulant Therapy, Hematoma Treatment, Novel Anticoagulants, Chronic Care Model, Chronic Disease Management, Wagner Chronic Care Model, Thrombolytics, Treatment of Pulmonary Embolism, Warfarin Monitoring, Clotting Factors |
Other Titles | Patients on Anticoagulant Therapy With and Without Hematoma Enlargement, Chronic Care Anticoagulant Therapy Management, Warfarin Dosage in Anticoagulant Chronic Care Management, Chronic Disease Management and Patient Outcomes, Thrombolysis Treatment for Pulmonary Embolism Complications |
Included Datasets
Characteristics of OAC Patients With and Without Hematoma Enlargement
The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed this study on behalf of IGNITE (Initiative of German Neuro Intensive Trial Engagement) and was published by The Journal of the American Medical Association (JAMA) on February 24, 2015. The study investigated the association of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and the effects of OAC resumption.
Chronic Care Management Differences in Anticoagulant Clinics
This research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy. The data were subjected to regression analysis to identify to what extent the differences in patient outcomes are associated with chronic care management activities.
Chronic Care Management Patient Outcomes in Anticoagulant Regions
This research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy (OAT). This study was performed to identify the differences in patient outcomes and their relationship with chronic care management of OAT.
Participant Characteristics Anticoagulants Randomized Trial JAMA
This clinical investigation that was published in The Journal of the American Medical Association (JAMA) on June 18, 2014, was a collaboration of efforts from PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science, and CINAHL since its inception from April 10, 2014.
Pulmonary Embolism Thrombolysis Treatment and Its Complications JAMA
This clinical investigation that was published in The Journal of the American Medical Association (JAMA) on June 18, 2014, was a collaboration of efforts from PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science, and CINAHL since its inception from April 10, 2014. The goal of the study was to determine the risks and complications involved with thrombolytic therapy compared with anticoagulation in acute pulmonary embolism.
Subgroup Analysis for Mode of Reversal Treatment FFP vs PCC
The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed this study on behalf of IGNITE (Initiative of German Neuro Intensive Trial Engagement) and was published by The Journal of the American Medical Association (JAMA) on February 24, 2015. The study compared outcome for patients using two different mode of reversal treatments: (1) Fresh Frozen Plasma (FFP), and (2) Prothrombin Complex Concentrates (PCC).
Data Engineering Overview
We deliver high-quality data
- Each dataset goes through 3 levels of quality review
- 2 Manual reviews are done by domain experts
- Then, an automated set of 60+ validations enforces every datum matches metadata & defined constraints
- Data is normalized into one unified type system
- All dates, unites, codes, currencies look the same
- All null values are normalized to the same value
- All dataset and field names are SQL and Hive compliant
- Data and Metadata
- Data is available in both CSV and Apache Parquet format, optimized for high read performance on distributed Hadoop, Spark & MPP clusters
- Metadata is provided in the open Frictionless Data standard, and its every field is normalized & validated
- Data Updates
- Data updates support replace-on-update: outdated foreign keys are deprecated, not deleted
Our data is curated and enriched by domain experts
Each dataset is manually curated by our team of doctors, pharmacists, public health & medical billing experts:
- Field names, descriptions, and normalized values are chosen by people who actually understand their meaning
- Healthcare & life science experts add categories, search keywords, descriptions and more to each dataset
- Both manual and automated data enrichment supported for clinical codes, providers, drugs, and geo-locations
- The data is always kept up to date – even when the source requires manual effort to get updates
- Support for data subscribers is provided directly by the domain experts who curated the data sets
- Every data source’s license is manually verified to allow for royalty-free commercial use and redistribution.
Need Help?
- If you have questions about our products, contact us at info@johnsnowlabs.com.
About Us
John Snow Labs , an AI and NLP for healthcare company, provides state-of-the-art software, models, and data to help healthcare and life science organizations build, deploy, and operate AI projects.
Provided By
Fulfillment Method
AWS Data Exchange
Data dictionaries
A data dictionary is a visual representation of the contents of a data set. The data represented here is for evaluation purposes only and may not accurately represent the actual content of the product.
Field name | Description | Example | Data type | Primary key | Nullable | Max length | Data set | Table name | Table description |
---|---|---|---|---|---|---|---|---|---|
Clinical_Characteristics_of_Patients | Description of the characteristics of the patients who participated in the clinical trial. | - | string | - | - | - | Characteristics of OAC Patients With and Without Hematoma Enlargement | characteristics_of_oac_patients_with_and_without_hematoma_enlargement | |
Criteria_Parameters | Description of the parameters used in the selection of criteria and measurement of the outcomes of the clinical trial. | - | string | - | false | - | Characteristics of OAC Patients With and Without Hematoma Enlargement | characteristics_of_oac_patients_with_and_without_hematoma_enlargement | |
Patients_With_Hematoma_Enlargement | Description of the number of patients with hematoma enlargement after use of oral anticoagulants. | - | integer | - | - | - | Characteristics of OAC Patients With and Without Hematoma Enlargement | characteristics_of_oac_patients_with_and_without_hematoma_enlargement | |
Percentage_of_Patients_With_Hematoma_Enlargement | Description of the percentage of patients with hematoma enlargement after use of oral anticoagulants. | - | numeric | - | - | - | Characteristics of OAC Patients With and Without Hematoma Enlargement | characteristics_of_oac_patients_with_and_without_hematoma_enlargement | |
Standard_Deviation_Interquartile_Range_of_Variables_With_Hematoma | Description of either standard deviations or interquartile range of the variables in relation to the results according to the parameters of the clinical trial. | - | string | - | - | - | Characteristics of OAC Patients With and Without Hematoma Enlargement | characteristics_of_oac_patients_with_and_without_hematoma_enlargement | |
Patients_Without_Hematoma_Enlargement | Description of the number of patients without hematoma enlargement after use of oral anticoagulants. | - | integer | - | - | - | Characteristics of OAC Patients With and Without Hematoma Enlargement | characteristics_of_oac_patients_with_and_without_hematoma_enlargement | |
Percentage_of_Patients_Without_Hematoma_Enlargement | Description of the percentage of patients without hematoma enlargement after use of oral anticoagulants. | - | numeric | - | - | - | Characteristics of OAC Patients With and Without Hematoma Enlargement | characteristics_of_oac_patients_with_and_without_hematoma_enlargement | |
Standard_Deviation_Interquartile_Range_of_Variables_Without_Hematoma | Description of either standard deviations or interquartile range of the variables in relation to the results according to the parameters of the clinical trial. | - | string | - | - | - | Characteristics of OAC Patients With and Without Hematoma Enlargement | characteristics_of_oac_patients_with_and_without_hematoma_enlargement | |
Probability | Description of effectiveness of the results of the clinical trial based on the hypothesis of the study. | 0.08 | string | - | - | - | Characteristics of OAC Patients With and Without Hematoma Enlargement | characteristics_of_oac_patients_with_and_without_hematoma_enlargement | |
Chronic_Care_Management_Elements | Description of the components of the Chronic Care Management used in different Dutch Anticoagulant Clinic (AC) regions. | - | string | - | - | - | Chronic Care Management Differences in Anticoagulant Clinics | chronic_care_management_differences_in_anticoagulant_clinics |
Data sets (6)
You will receive access to the following data sets
Revision access rules
All historical revisions | All future revisions
Name | Type | Data dictionary | AWS Region |
---|---|---|---|
Subgroup Analysis for Mode of Reversal Treatment FFP vs PCC | Included | US East (N. Virginia) | |
Pulmonary Embolism Thrombolysis Treatment and Its Complications JAMA | Included | US East (N. Virginia) | |
Participant Characteristics Anticoagulants Randomized Trial JAMA | Included | US East (N. Virginia) | |
Chronic Care Management Patient Outcomes in Anticoagulant Regions | Included | US East (N. Virginia) | |
Chronic Care Management Differences in Anticoagulant Clinics | Included | US East (N. Virginia) | |
Characteristics of OAC Patients With and Without Hematoma Enlargement | Included | US East (N. Virginia) |
Data dictionaries and samples
Sample data is for evaluation purposes only and may not accurately represent the actual content of the product.
Name | Resource | File type | File size | Description | ||
---|---|---|---|---|---|---|
Characteristics of OAC Patients With and Without Hematoma Enlargement | Data set | - | - | - | ||
Data dictionary | Data dictionary | text/csv | - | |||
data_preview.csv | Sample | text/csv | Preview of Characteristics of OAC Patients With and Without Hematoma Enlargement dataset | |||
Chronic Care Management Differences in Anticoagulant Clinics | Data set | - | - | - | ||
Chronic Care Management Patient Outcomes in Anticoagulant Regions | Data set | - | - | - | ||
Participant Characteristics Anticoagulants Randomized Trial JAMA | Data set | - | - | - | ||
Pulmonary Embolism Thrombolysis Treatment and Its Complications JAMA | Data set | - | - | - | ||
Subgroup Analysis for Mode of Reversal Treatment FFP vs PCC | Data set | - | - | - |
Usage information
By subscribing to this product, you agree that your use of this product is subject to the provider's offer terms including pricing information and Data Subscription Agreement . Your use of AWS services remains subject to the AWS Customer Agreement or other agreement with AWS governing your use of such services.
Support information
Support contact email address
Support contact URL
Refund policy
“No refunds offered. For any questions email us at info@johnsnowlabs.com”
General AWS Data Exchange support